TY -的T1 -肺hypertensio患病率n in pulmonary sarcoidosis: the first large European prospective study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00897-2019 VL - 54 IS - 4 SP - 1900897 AU - Huitema, Marloes P. AU - Bakker, Annelies L.M. AU - Mager, Johannes J. AU - Rensing, Benno J.W.M. AU - Smits, Fokko AU - Snijder, Repke J. AU - Grutters, Jan C. AU - Post, Marco C. Y1 - 2019/10/01 UR - //www.qdcxjkg.com/content/54/4/1900897.abstract N2 - Sarcoidosis is a systemic disease of an unknown aetiology, in which noncaseating granulomas are formed in one or multiple organs, with pulmonary involvement in >90% of the sarcoidosis patients [1]. Pulmonary hypertension (PH), defined as a mean pulmonary artery pressure of ≥25 mmHg by right heart catheterisation (RHC) [2], is a well recognised complication of sarcoidosis, associated with significant increase in mortality [3, 4]. Although the first case of PH in sarcoidosis was described in 1949 [5], the exact prevalence remains unclear.The prevalence of pulmonary hypertension in sarcoidosis seems to differ between ethnicities and was never investigated in a Caucasian cohort. This study shows a prevalence of 3% in a Caucasian cohort, significantly lower compared to other ethnicities. http://bit.ly/2kRMrap ER -